-
Direct and Indirect Economic Burden Due to Chronic Limb-Threatening Ischemia (CLTI) in Germany
Sep 9, 2025, 16:22 PM -
Characterizing the Use of Janus Kinase Inhibitors (JAKi) in Five European Countries: A Drug Utilization Study
Sep 9, 2025, 16:22 PM -
Economic Burden Associated With Type 2 Diabetes Mellitus in France: An Update From the National Insurance Claim Database
Sep 9, 2025, 16:22 PM -
Public Health Impact of Herpes Zoster Vaccination in Immunocompromised Adults Aged 18-49 Years in the United Kingdom
Sep 9, 2025, 16:22 PM -
Indirect Comparison of Tarlatamab vs. Chemotherapy (CTx) in Patients With Previously Treated, Platinum-Refractory, or Resistant Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Sep 9, 2025, 16:22 PM -
Improving Data Quality in Oncology Electronic Health Record (EHR)-Derived Databases for Research and Regulatory Decision Making
Sep 9, 2025, 16:22 PM -
Cost of Adverse Events With the Bruton Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia in Brazil
Sep 9, 2025, 16:22 PM -
Evaluating the Cost-Effectiveness of Adjuvanted Influenza Vaccine in the Older Adult Population in the Netherlands
Sep 9, 2025, 16:22 PM -
Matching-Adjusted Indirect Comparisons (MAICs) and Network Meta-Analyses (NMAs) of the Oral Small-Molecule Chaperone Migalastat vs. Intravenous Enzyme Replacement Therapies (ERTs) for Clinical Measures in Fabry Disease
Sep 9, 2025, 16:22 PM -
The Use of Real-World Evidence in Health Technology Assessment and the Application of the NICE RWE Framework: A Review of NICE Technology Appraisals
Sep 9, 2025, 16:22 PM -
Healthcare Costs in Older Adults: XGBoost, NNA, and Logit
Sep 9, 2025, 16:22 PM -
Beyond the QALY: An Analysis of Uncaptured Benefits in NICE Oncology Technology Appraisals 2023-2025
Sep 9, 2025, 16:22 PM -
How Are Clinical Trials for Breast Cancer Treatments Currently Being Designed? A Clinical Trial Database Analysis
Sep 9, 2025, 16:22 PM -
Understanding Reimbursement and Access Policies for Immunoglobulins and Other Plasma-Derived Medicinal Products Across Europe
Sep 9, 2025, 16:22 PM -
Comparative Analysis of Reimbursement Decisions for Advanced Oncology Combination Therapies in England and Japan
Sep 9, 2025, 16:22 PM -
Quantifying the Fiscal Value of Prevention Programs for Depression
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Analysis of Pembrolizumab in Combination With Enfortumab Vendotin for First-Line Treatment of Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Sep 9, 2025, 16:22 PM -
Trends in Receipt of Preventive Healthcare Services from 2020-2024: US Electronic Health Records (EHR) Database Analysis of 118 Million Patients
Sep 9, 2025, 16:22 PM -
Real-World Burden of Illness in Patients With ER+/HER2- ABC Receiving Second-Line Treatment: Interim Results of Longitudinal Health Utility Data
Sep 9, 2025, 16:22 PM -
Thecosystem: A Systemwide Health and Social Care Decision Analytical Model to Assess Population-Based Interventions for Older People’s Care in the UK
Sep 9, 2025, 16:22 PM
